BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 11366575)

  • 1. FDA hearing highlights opposition to dietary supplement practices; written comments due August 20. Food and Drug Administration.
    James JS
    AIDS Treat News; 1999 Aug; (No 324):3-4. PubMed ID: 11366575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ephedra: yesterday, DSHEA, and tomorrow--a ten year perspective on the Dietary Supplement Health and Education Act of 1994.
    Seamon MJ; Clauson KA
    J Herb Pharmacother; 2005; 5(3):67-86. PubMed ID: 16520299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Re-thinking the dietary supplement laws and regulations 14 years after the Dietary Supplement Health and Education Act implementation.
    Jiang T
    Int J Food Sci Nutr; 2009 Jun; 60(4):293-301. PubMed ID: 19085198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The importance of GRAS to the functional food and nutraceutical industries.
    Burdock GA; Carabin IG; Griffiths JC
    Toxicology; 2006 Apr; 221(1):17-27. PubMed ID: 16483705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FDA regulation of dietary supplements and requirements regarding adverse event reporting.
    Frankos VH; Street DA; O'Neill RK
    Clin Pharmacol Ther; 2010 Feb; 87(2):239-44. PubMed ID: 20032973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proposed rule: current good manufacturing practice in manufacturing, packing, or holding dietary ingredients and dietary supplements.
    Melethil S
    Life Sci; 2006 Mar; 78(18):2049-53. PubMed ID: 16516243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can claims, misleading information, and manufacturing issues regarding dietary supplements be improved in the United States?
    Gibson JE; Taylor DA
    J Pharmacol Exp Ther; 2005 Sep; 314(3):939-44. PubMed ID: 15833895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Iron-containing supplements and drugs; label warning statements and unit-dose packaging requirements; removal of regulations for unit-dose packaging requirements for dietary supplements and drugs. Final rule; removal of regulatory provisions in response to court order.
    Food and Drug Administration, HHS
    Fed Regist; 2003 Oct; 68(201):59714-5. PubMed ID: 14567392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulations on statements made for dietary supplements concerning the effect of the product on the structure or function of the body. Food and Drug Administration, HHS. Final rule.
    Fed Regist; 2000 Jan; 65(4):1000-50. PubMed ID: 11010621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of cGMP compliance on consumer confidence in dietary supplement products.
    Crowley R; FitzGerald LH
    Toxicology; 2006 Apr; 221(1):9-16. PubMed ID: 16469425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dietary supplements and lessons to be learned from GRAS.
    Burdock GA
    Regul Toxicol Pharmacol; 2000 Feb; 31(1):68-76. PubMed ID: 10715226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physicians' understanding of the regulation of dietary supplements.
    Ashar BH; Rice TN; Sisson SD
    Arch Intern Med; 2007 May; 167(9):966-9. PubMed ID: 17502539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FDA perspectives on supplement use by patients on antithrombotic therapy: dietary supplement regulatory overview.
    Woo JJ
    Thromb Res; 2005; 117(1-2):193-6; discussion 201-7. PubMed ID: 16253311
    [No Abstract]   [Full Text] [Related]  

  • 14. Influence of the dietary supplement health and education act on consumer beliefs about the safety and effectiveness of dietary supplements.
    Dodge T; Litt D; Kaufman A
    J Health Commun; 2011 Mar; 16(3):230-44. PubMed ID: 21120738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FDA perspectives on supplement use by patients on antithrombotic therapy.
    Kim MJ
    Thromb Res; 2005; 117(1-2):197-200; discussion 201-7. PubMed ID: 16188297
    [No Abstract]   [Full Text] [Related]  

  • 16. Dietary supplement labeling and advertising claims: are clinical studies on the full product required?
    Villafranco JE; Bond K
    Food Drug Law J; 2009; 64(1):43-67. PubMed ID: 19998572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current good manufacturing practice in manufacturing, packaging, labeling, or holding operations for dietary supplements. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2007 Jun; 72(121):34751-958. PubMed ID: 17674484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Dietary Supplement Health and Education Act.
    Young AL; Bass IS
    Food Drug Law J; 1995; 50(2):285-92. PubMed ID: 10342995
    [No Abstract]   [Full Text] [Related]  

  • 19. Dietary supplement adverse event reports: review and analysis.
    Talati AR; Gurnani AK
    Food Drug Law J; 2009; 64(3):503-13. PubMed ID: 19999641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A survey of developments in food and drug law from July 1998 to November 1999.
    Littlefield N; Hada NR
    Food Drug Law J; 2000; 55(1):35-56. PubMed ID: 12296348
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.